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Cutaneous B-cell lymphomas: 2015 update on diagnosis,
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Disease overview: Approximately one-fourth of cutaneous lymphomas are B-cell derived and are generally
classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary
cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B-cell lymphoma, leg
type (PCDLBCL, LT).
Diagnosis: Diagnosis and disease classification is based on histologic review and immunohistochemical staining of
an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish
primary cutaneous B-cell lymphomas from systemic B-cell lymphomas with secondary skin involvement.
Risk-stratification: Disease histology remains the most important prognostic determinant. Both PCFCL and
PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated
with 5-year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an
inferior prognosis.
Risk-adapted therapy: PCFCL and PCMZL patients with solitary or relatively few skin lesions may be affectively
managed with local radiation therapy. While single-agent rituximab may be employed for patients with more
widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of
patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL.
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 Disease Overview
Primary cutaneous lymphomas are a heterogenous group of extranodal non-Hodgkin lymphomas, approximately 25% of which are B-
cell derived and are classified into three major entities in the 2008 World Health Organization (WHO)-European Organization for
Research and Treatment of Cancer (EORTC) joint classification: primary cutaneous follicle-center lymphoma (PCFCL), primary cutaneous
diffuse large B-cell lymphoma, leg type (PCDLBCL, LT), and primary cutaneous marginal zone lymphoma (PCMZL) [1]. The incidence of
cutaneous B-cell lymphomas (CBCL) has been increasing and is currently 3.1 per million persons, based on Surveillance, Epidemiology,
and End Results (SEER) registry data, with the highest incidence rates being reported among males, non-Hispanic whites, and adults over
the age of 50 [2].
 Diagnosis
Diagnosis and classification of a CBCL requires an excisional or punch biopsy for careful morphologic and immunohistochemical analysis, and
an appropriate staging evaluation to exclude systemic disease [3]. The use of appropriate immunohistochemical stains (e.g., CD5, cyclin D1) may
also aid in distinguishing CBCL from secondary skin involvement by a systemic lymphoma.
PCFCL
PCFCL are commonly solitary plaques or tumors involving the trunk, particularly the head or scalp. While grouped lesions may be observed,
multifocal disease is less common. Histologically, PCFCL are characterized by a follicular, diffuse, or mixed growth pattern comprised of large cen-
trocytes derived from germinal center B cells [1,4,5]. In contrast to systemic follicular lymphomas, the majority of PCFCL do not harbor the
t(14;18) translocation involving the bcl-2 locus, and do not strongly express bcl-2 by immunohistochemistry, although weak expression may be
observed in a minority of cases [6–8]. These CBCL express bcl-6, variably express CD10, and are MUM-1/IRF-4 negative, consistent with their ori-
gin from germinal center B cells.
PCDLBCL, LT
In contrast to PCFCL, which is an indolent CBCL largely involving the head and trunk commonly affecting middle-aged adults, PCDLBCL,
leg type commonly affects elderly females and presents with rapidly progressive tumors involving the lower legs [9,10]. Approximately 10% of
cases may involve other cutaneous sites apart from the lower legs, and extracutaneous dissemination is common [10]. These lymphomas are
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characterized by diffuse sheets of centroblasts and immunoblasts
that spare the epidermis, but frequently extend deep into the dermis
and subcutaneous tissue. In contrast to PCFCL, lymphoma cells
highly express bcl-2, likely due to gene amplification [11], as
t(14;18) is not observed in PCDLBCL, LT. Most cases are MUM-1/
IRF-4 and bcl-6 positive, CD10 negative, and have a gene expression
profile resembling activated B cells [5]. Perhaps not surprisingly, the
genetic landscape observed in PCDLBCL, LT is similar to that
observed in activated B-cell-type diffuse large B-cell lymphoma
(ABC-DLBCL), with NF-jB-activating mutations being observed in
CD79B, CARD11, and MYD88 [12,13]. Of these, somatic
MYD88 L265P mutations appear most common, with a prevalence
of 59% in the largest series [13].
PCMZL
Patients with PCMZL frequently present with multifocal patches,
plaques or nodules involving the trunk and arms. While an associa-
tion with Borrelia burgdorferi has been observed in Europe, a similar
association has not been observed in cases from the United States
[14–17]. PCMZL are composed of a mixed infiltrate of small, mar-
ginal zone B cells, lymphoplasmacytic cells, plasma cells, and reactive
T cells. Marginal zone B cells characteristically express bcl-2, but lack
bcl-6 or CD10 expression.
 Risk-Stratification
The International Society for Cutaneous Lymphomas (ISCL) and
EORTC recently proposed staging recommendations for cutaneous
lymphomas other than mycosis fungoides and Sezary syndrome
[3]. Staging should include a history, physical examination, appro-
priate laboratory studies (including lactate dehydrogenase), and
imaging (either CT, PET, or increasingly PET/CT) of the chest,
abdomen, pelvis, and neck (in cases with involvement of the head
or neck). A bone marrow biopsy and aspirate should be performed
in cases of PCDLBCL, LT. While the joint ISCL/EORTC does not
endorse routine bone marrow examination in cases of PCFCL or
PCMZL, approximately 10% of patients with PCFCL have bone
marrow involvement [18]. Furthermore, bone marrow involvement
was associated with significantly inferior disease-specific survival.
Therefore, in the opinion of this author, bone marrow examination
is justified in cases of PCFCL. While the TNM staging classifica-
tion describes the extent of disease, staging in CBCL is of limited
prognostic value, as the disease histology is the major determinant
in risk-stratification. This is highlighted by a population-based
study which identified histology and the site of skin involvement
as important prognostic factors [19]. In contrast, the International
Extranodal Lymphoma Study Group identified three independent
prognostic factors (i.e., elevated LDH, >2 skin lesions, and nodular
lesions) among patients with PCFCL and PCMZL. These factors
were combined to form the cutaneous lymphoma international
prognostic index (CLIPI). The absence of any adverse prognostic
factor was associated with a 5-year progression-free survival of
91%. In contrast, the presence of two or three adverse prognostic
factors was associated with a 5-year progression-free survival of
48%. As the vast majority of relapses were confined to the skin,
the CLIPI was unable to risk-stratify patients by overall survival.
The presence of multiple skin lesions was associated with inferior
disease-free survival in a European series [20], but was not associ-
ated with disease-free survival in a large North American series
[21]. The most important factor for risk-stratification among the
CBCLs remains the histologic classification. Indolent CBCL
(PCFCL and PCMZL) are associated with 5-year disease-specific
survival 95% [1,21]. Differences in growth pattern, the density of
centroblasts, and cytogenetic findings do not appear to provide
meaningful prognostic information. Bcl-2 expression among
PCFCL with a diffuse large B-cell histology may be a notable
exception [22]. In contrast, PCDLBCL, LT is associated with a 5-
year disease-specific survival of approximately 50% and with cyto-
genetic changes, including translocations involving c-myc, that
confer a poor prognosis among systemic DLBCLs [1,13,23]. The
presence of a somatic MYD88 L265P mutation is also associated
with inferior disease-specific and overall survival [13]. In contrast
to patients presenting with only a single tumor, involvement of
multiple sites, on one or both legs, is associated with a significantly
inferior disease-specific survival [24].
 Treatment
As no randomized, controlled trials are available, treatment recom-
mendations for CBCL are largely based on small retrospective studies
and institutional experience. The EORTC and ISCL have published
consensus treatment recommendations that are consistent with
NCCN guidelines [25]. In most cases, optimal patient management
requires a multidisciplinary approach, including dermatology, medical
oncology, and radiation oncology.
PCFCL
For patients with solitary lesions, radiation therapy is safe and
highly affective, with a complete remission rate approaching 100%.
Radiation does not appear inferior to multiagent chemotherapy
among patients with multiple lesions that can be included in multi-
ple radiation fields [26]. In a large North American series, the rate
of local control for indolent CBCL with radiation alone was 98%
[21]. In the same series, a local recurrence requiring radiation ther-
apy was observed in 25% of patients who had undergone surgical
excision alone. Reserving radiation until disease recurrence did not
appear to compromise disease-specific or overall survival [21].
Therefore, complete excision alone, deferring radiation until disease
recurrence, may be reasonable. While radiation therapy is generally
recommended for patients with a solitary lesion, radiation therapy,
or observation (i.e., “watch and wait”) are reasonable options for
those patients with multiple lesions. Patients with more extensive
skin involvement are effectively managed with single-agent rituxi-
mab [25]. Multiagent chemotherapy (e.g., R-CHOP) is rarely
required in the management of PCFCL. Approximately one-third of
patients may relapse following either radiation or single-agent ritux-
imab, but relapses are usually confined to the skin and are
approached in a manner similar to that described for the initial
management of PCFCL.
PCMZL
Patients with PCMZL are approached in a manner analogous to
that described in the initial management of PCFCL. Radiation therapy
is associated with a similarly high response rate for patients with a
single or few lesions [25]. Those with more widespread skin involve-
ment may be observed. Once symptomatic, culprit lesion may be irra-
diated (or surgically excised). As for PCFCL, single-agent rituximab
may be utilized in patients with symptomatic, widespread skin
lesions. An initial trial of antibiotics for those with B. burgdorferi-
associated PCMZL has been recommended [27], but is less relevant
for North American patients.
PCDLBCL, LT
As previously noted, the natural history of PCDLBCL, LT more
closely resembles that of systemic DLBCL. Therefore, R-CHOP (with
or without radiation therapy) is utilized in these patients. While few
reports are available in the literature, the use of R-CHOP in these
patients is associated with disease-free survival rates rivaling those
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reported for patients with high-risk systemic DLBCL [9,10,21,25].
Most patients present with disease confined to the leg(s) and are
managed like patients with limited stage systemic DLBCL with R-
CHOP and involved field radiation therapy. The management of
relapsed disease is comparable to that for relapsed systemic ABC-
DLBCL (e.g., lenalidomide [28]).
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